Life Science Investing Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
Life Science Investing Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
Life Science Investing Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® in Adults with Moderate Atopic Dermatitis
Life Science Investing Incyte Announces Phase 1 Results for its TGF?R2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
Life Science Investing Data from Incyte's TGF?R2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology Congress 2025
Life Science Investing Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
Life Science Investing Incyte Announces Additional FDA Approval of Opzelura® Cream in Children Ages 2-11 with Atopic Dermatitis
Life Science Investing Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
Life Science Investing Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
Life Science Investing Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
